Navigation Links
Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
Date:8/25/2009

uld have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Only the FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Further, the scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration (FDA) for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the FDA-approved labeling for the products, and not the information discussed in this news release.

    CONTACT: Amgen, Thousand Oaks
    Emma Hurley: 805-447-7845 (media)
    Arvind Sood: 805-447-1060 (investors)

(Logo: http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO)


'/>"/>
SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
2. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
3. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
6. Medarex to Receive Milestone Payment from Amgen
7. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
8. ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09%
9. IDEV(R) Technologies Announces First Patient Enrolled in Multi-Center Clinical Trial of SUPERA(R) PERipheral Stent
10. Phytomedics Inc. Announces Publication of the Phase 2b Clinical Trial Results of an Extract of the Chinese Herbal Remedy Tripterygium wilfordii Hook F in Rheumatoid Arthritis
11. Bionovo Announces Second Quarter 2009 Highlights and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  Kinex Pharmaceuticals announced the receipt of ... KX2-391 Ointment for the commencement of a Phase I ... third IND to be allowed by the US FDA ... a synthetic, orally active and highly selective inhibitor of ... the induction of p53, G2/M arrest of proliferating cell ...
(Date:7/24/2014)... 2014 Consolidated Net Profit increased by 43.65 ...   , India Business grew by 20.87% to Rs. ... 4,886.70 Mn Rest of World (ROW) Business grew by ... by 34.53% to Rs. 977.26 Mn Latin America Business ... Glenmark Pharmaceuticals Limited, the research-led global integrated pharmaceutical company, today ...
(Date:7/24/2014)... 2014 Boston Children,s Hospital,s Global Pediatric Summit ... feature an "Innovation Tank" – a forum designed to ... their business or product solution to a panel of ... how to accelerate the innovation and bring it to ... Friday, October 31, will be moderated by Daymond ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 2Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 3
... July 12, 2011 Vapotherm, a privately held manufacturer of ... that it has signed a new exclusive distribution agreement with ... Korea for the Vapotherm acute care product line. ... Hippo to bring high flow therapy to the Korean market," ...
... 12, 2011 UBM TechInsights, the leader in technical ... announced today that medical devices industry veteran Bill Betten ... Devices.  In this role Mr. Betten will draw upon ... medical device sector maximize the effectiveness of the product ...
Cached Medicine Technology:Vapotherm Announces New Exclusive Distribution Agreement with Hippo Medical for South Korea 2UBM TechInsights Hires Medical Devices Industry Veteran Bill Betten 2
(Date:7/25/2014)... Tampa, FL (PRWEB) July 25, 2014 ... launches their innovative toothbrushes with antibacterial silver that naturally kill ... land on the brush. , A toothbrush is the ... diseases, dental health and hygiene, however, it is subject to ... the air. , There are more bacteria in the mouth ...
(Date:7/24/2014)... 2014 Dr. Henry H. Ting, a ... has been appointed senior vice president and chief quality ... his new role, he will oversee the hospital's clinical ... successfully led quality initiatives and interprofessional teams at the ... for the Door-to-Balloon Alliance, a collaboration of more than ...
(Date:7/24/2014)... to light at night, which shuts off nighttime production ... to tamoxifen, a widely used breast cancer drug, says ... cancer researchers. The study, "Circadian and Melatonin Disruption by ... Tamoxifen Therapy in Breast Cancer," published in the journal ... that melatonin is vital to the success of tamoxifen ...
(Date:7/24/2014)... Park, NC (PRWEB) July 24, 2014 ... ethnic minorities, and low-income households are disproportionately affected ... public food safety net in the United States, ... , Under Section 743 of the Consolidated Appropriations ... Department of Agriculture's Food and Nutrition Service (FNS) ...
(Date:7/24/2014)... Monica, CA (PRWEB) July 24, 2014 ... health seriously, they must consider their own financial and ... flabby and weak marketing campaigns to the next level ... CallFire’s Cloud Call Center, IVR, Voice Broadcast, Call Tracking ... than a 98% open rate, text messages are quickly ...
Breaking Medicine News(10 mins):Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 2Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 3Health News:NewYork-Presbyterian Hospital Names New Senior Vice President for Quality and Patient Safety 2Health News:NewYork-Presbyterian Hospital Names New Senior Vice President for Quality and Patient Safety 3Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:Report: Vulnerable Populations Disproportionately Affected by Food Security, Despite Public Programs 2Health News:Report: Vulnerable Populations Disproportionately Affected by Food Security, Despite Public Programs 3Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 2Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 3
... that a new strain of E. coli O157was responsible for ... in Europe and Australia, but is apparently very rare in ... the laboratory from other types of E.coli O157 and this ... it,' said HPS consultant Dr John Cowden. 'It produces the ...
... In a bid to save its plummeting sales of chicken ... //The campaign would ensure that the customers get ... been planned by McDonald’s Corp., of Oakbrook, Ill. , ... ensure that is a epidemic and bird flu scare spread ...
... study that was published in Urology Journal BJUI International has ... and almost half of 19-year-olds who have a problem are ... the Chinese University of Hong Kong and the Prince of ... questionnaires surveying children who were aged 5 to 19. The ...
... popular drug for depression has been studied by researchers, in ... from the Cold Spring Harbor Laboratory// in Long Island, New ... immature brain cells. ,This could pave the way ... Alzheimer's. The researchers, as part of their study, analyzed proteins ...
... 2007, cigarette packets will carry graphic representations depicting the dangerous ... ward off the smoking habit. The pictorial representation could be ... womb. ,A website installed by the Department of Health, ... range of pictures that intend to underline the pitfalls of ...
... is a private company and was set up in 1994 in ... accepted to provide health care facility// free of cost to NHS ... General Practitioners for 7,000 patients and employ 3 doctors and 7 ... in London. ,The deal has been signed by ...
Cached Medicine News:
... a broad selection of tip styles ... of ophthalmic procedures. Each single use ... a safety cap to lock switch ... not in use, and carries a ...
... Accu-Temp Cauteries provide a broad ... in a wide variety of ophthalmic ... packaged sterile, complete with a safety ... "off " position when not in ...
... The Luminary LASIK Light Probes provide ... that allows the corneal interface to be ... use of the Tindal effect and light ... of interface debris, epithelial deposits, flap edge ...
... EEG system designed to satisfy the needs ... center. Ready to use, Comet XL is ... and Photic Stimulator. Select from various mobile ... your individual needs. These powerful, easy-to-use EEG ...
Medicine Products: